Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Lupin Pharmaceuticals Expands Coral Springs, Florida, Operations

10/18/2025
Global pharmaceutical company Lupin Pharmaceuticals plans to expand its operations in Coral Springs, Florida. The $250 million project is expected to create more than 200 jobs by 2030 in Broward County.

The investment will include the construction of a new manufacturing facility that will have the capacity to accommodate the production of more than 25 critical respiratory medicines.

"The expansion of Lupin's footprint in Coral Springs is a core part of our growth strategy. This new?state-of-the-art?facility will build on our existing presence in Florida, which is home to Lupin's headquarters and our Advanced Inhalation Research Center. This investment?demonstrates?Lupin's commitment to innovation,?quality?and supply chain reliability — and our ability to partner with Florida's leaders to strengthen America's medicine security by growing our capacity to produce affordable treatments for patients.?We?are grateful?to Florida's leadership?for their?partnership in making this?possible," said Christoph Funke, Chief Technical Operations Officer, Lupin.

To support the project Lupin will receive tax credits and incentives from the state of Florida.

"On behalf of FloridaCommerce, I'm excited to welcome Lupin's expansion in Coral Springs and the high-impact investment it brings to our state," noted Florida Secretary of Commerce J. Alex Kelly. "Thanks to Governor DeSantis' leadership, Florida has built a strong foundation for growth—with a strong focus on research and development, nine consecutive years as the #1 state for postsecondary education and three consecutive years as the #1 state for talent development, Florida has become #2 in the nation for both pharmaceutical and medical device manufacturing. Lupin's investment will strengthen Florida's position as a leader in life sciences, boost our advanced manufacturing capabilities and enhance the state's medicine security—delivering long-term benefits to both our economy and the health of Floridians."

Lupin Pharmaceuticals, the U.S. subsidiary of India-based Lupin Limited, produces a wide range of generic, branded, and specialty medications for various therapeutic areas.

Exclusive Research